arrow
L

Laurent Frenzel

Necker Hospital
H指数:27
被引数:5,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
Patients', family caregivers', and professionals' perspectives on the quality of cancer drug injections at home: A qualitative and comparative study in France

患者、家庭照护者及专业人士对居家癌症药物注射质量的视角:一项在法国进行的定性比较研究

2026-08-260
PRE
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Real-world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study

新诊断多发性骨髓瘤中阿哌沙班与标准血栓预防措施的安全性和有效性的真实世界研究:来自一项多中心回顾性队列研究的见解

2026-08-210
PRE
Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study

在非研究性产品研究中对血友病A和B患者出血率和因子使用情况进行前瞻性收集

2026-08-010
PRE
Nationwide rollout of gene therapy for hemophilia B in France From theoretical planning to organizational improvement: Lessons learned after three years

法国血友病B基因治疗的全国推广:从理论规划到组织改进——三年经验教训

2026-05-010
PRE
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

替雷利珠单抗在老年复发/难治性多发性骨髓瘤患者中的应用:法国回顾性队列研究的亚组分析

2026-02-010
OAAI
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression

TRF2在端粒上的定位受KIT突变影响,并与肥大细胞增多症的消退相关。

2025-11-050
OAAI
Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: Results from the BENEGENE-2 trial

接受fidanacogene elaparvovec基因治疗的血友病B患者成年人的健康相关生活质量:BENEGENE-2试验的结果

2025-10-170
PRE
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

脆弱及新诊断多发性骨髓瘤患者中地塞米松减量方案联合达拉珠单抗和来那度胺的安全性与有效性(IFM2017-03):一项III期、开放标签、多中心、随机对照试验

2025-09-290
OAAI
High-risk genomic consensus validation in newly diagnosed multiple myeloma patients using next-generation sequencing

使用下一代测序对 newly diagnosed multiple myeloma 患者进行高风险基因组共识验证

Blood
IF23.1
2025-09-260
PRE
Real-world utilization of carfilzomib (once or twice weekly) initiated in patients after a first relapse between 2017-2022 in France: an analysis from a large-scale Epidemiology of Multiple MYeloma (EmmY) cohort

2017-2022年间法国在首次复发后的多发性骨髓瘤患者中开始使用卡非佐米(每周一次或两次)的实时应用:来自大规模多发性骨髓瘤流行病学(EmmY)队列的分析

2025-08-070
OAAI
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study

抗CD38单克隆抗体在初诊多发性骨髓瘤患者一线治疗中的影响:来自EMMY研究的真实世界结果

2025-07-240
PRE
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT

移植不适格的套细胞瘤患者在使用三联/四联疗法时的血栓栓塞:BENEFIT研究的后续分析

2025-06-140
PRE
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

一项关于modakafusp alfa作为单药治疗复发/难治性多发性骨髓瘤患者的2期随机研究

Blood
IF23.1
2025-04-290
OAAI